Physician profile
Emanuel Favela
NPI 1952614893
$528.91
in general payments reported to CMS, 2019-2025
9 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.61 · 2020: $80.22 · 2021: $13.66 · 2022: $122 · 2024: $135 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $137.54 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.19 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $97.26 | 2022 | |
| Glaxosmithkline, LLC. | $59.81 | 2020-2025 | Bexsero, Pediarix, Rotarix |
| Janssen Pharmaceuticals, INC | $39.30 | 2020 | |
| Penumbra, INC. | $25.63 | 2024 | Indigo System |
| Abbott Laboratories | $24.91 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.61 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emanuel Favela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.